Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

NCT04117958 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04117958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04117958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
January 20, 2020
Completion date
June 1, 2023
Enrollment
58 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

muc17-positive solid tumors